|
|
 |
|
Viewing report
|
|
|
|
Global Schizophrenia Drug Pipeline Capsule - 2012
Fore Pharma, Jan 2012, Pages: 14
Fore Pharma’s latest report ‘Global Schizophrenia Drug Pipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global schizophrenia drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.
This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.
The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the schizophrenia drug market is thoroughly covered by company and licensee with the deal summary.
Key Features of the Report:
- Schizophrenia: Overview
- Schizophrenia Drug Pipeline Overview
- Schizophrenia Phase 3 Clinical Trial Drug Pipeline Insights
- Schizophrenia Phase 2 Clinical Trial Drug Pipeline Insights
- Schizophrenia Phase 1 Clinical Trial Drug Pipeline Insights
- Schizophrenia Preclinical Research Drug Pipeline Insights
- Schizophrenia Drug Discovery Pipeline Insights
- Geographic Landscape of Schizophrenia R&D Activities
- Schizophrenia R&D Activities in North America
- Schizophrenia R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Schizophrenia Drug Market
|
|
|
|
